Q-omics provides the consensus-scored GALP profile across patient tissues and cancer cell-line models. GALP expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GALP is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, GALP RNA expression shows 6,723 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, CHOL, and STAD as cancer lineages where GALP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALP survival associations across molecular data types. GALP RNA expression shows survival associations in the most cancer types (14), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALP RNA expression–survival associations across cancer types. High GALP expression shows unfavorable associations in KIRC, KICH, LGG and ACC, but favorable associations in HNSC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify HNSC as the clearest survival context for GALP RNA expression.
This table summarizes GALP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for GALP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALP shows lower tumor expression in CHOL and higher tumor expression in UCEC and LUAD. The CHOL box plot shows higher GALP RNA expression in normal versus tumor tissue (log2 FC = −0.517, t-test p = .001).
This table shows molecular features associated with GALP in patient tissues and cancer cell lines. In patient samples, GALP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GALP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and CNS.
